Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

IMS 2024

21st International Myeloma Society Annual Meeting

25–28 September 2024 | Rio De Janeiro, Brazil

The 21st International Myeloma Society (IMS) Annual Meeting was held in Rio de Janeiro, Brazil, between September 25-28, 2024. This meeting brought together leading experts as they discussed the latest clinical and experimental advances in multiple myeloma.

View all videos

Comparing the thromboembolic risk with KRd versus VRd in newly diagnosed myeloma

Bruno Costa • 28 Oct 2024

Managing toxicities associated with bispecific T-cell engaging therapies in patients with myeloma

Wee Joo Chng • 26 Sep 2024

Interim results of a Phase II trial evaluating ISA-LEN for HR-SMM

Ola Landgren • 26 Oct 2024

Oral symptom assessment using PROs in patients with R/R myeloma treated with talquetamab

Rakesh Popat • 25 Sep 2024

Management of ocular events in patients treated with belantamab mafodotin plus PomDex in DREAMM-8

Hang Quach • 30 Sep 2024

CMV reactivation during treatment with bispecifics for R/R myeloma

Eric Jurgens • 25 Sep 2024

Managing frail patients with myeloma: assessing frailty and personalizing treatment

Mohamad Mohty • 27 Sep 2024

The prevalence of infections with bispecific use and managing patients who develop an infection

Meral Beksac • 26 Sep 2024

Updates on the QUINTESSENTIAL trial: second-generation anti-GPRC5D CAR-T in myeloma

Susan Bal • 27 Sep 2024

Real-world data modeling to evaluate cilta-cel in second vs third-line for refractory myeloma

Rafael Fonseca • 27 Sep 2024

Treating smoldering myeloma and the importance of improving patient selection

Sigurdur Kristinsson • 25 Sep 2024

Analyzing the BM immune microenvironment in RAS/RAF-mutated myeloma treated with a MEK inhibitor

Chaitanya Acharya et al. • 26 Sep 2024